has entered into a binding agreement with Switzerland-based NXI Therapeutics AG for development and supply of a New Chemical Entity targeting autoimmune disorders. The partnership includes comprehensive CMC development, GMP clinical supply, and commercial manufacturing support from early development through commercialization. This marks the third major international contract for Shilpa group in recent months, reinforcing its position as a strategic partner for global biotech companies in high-value therapeutic segments. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.